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ABSTRACT We have constructed a set of 42 plasmid shuttle vectors based on the widely used pRS series
for use in the budding yeast Saccharomyces cerevisiae and the bacterium Escherichia coli. This set of pRSII
plasmids includes new shuttle vectors that can be used with histidine and adenine auxotrophic laboratory
yeast strains carrying mutations in the genes HIS2 and ADE1, respectively. Our pRSII plasmids also include
updated versions of commonly used pRS plasmids from which common restriction sites that occur within
their yeast-selectable biosynthetic marker genes have been removed to increase the availability of unique
restriction sites within their polylinker regions. Hence, our pRSII plasmids are a complete set of integrating,
centromere and 2m episomal plasmids with the biosynthetic marker genes ADE2, HIS3, TRP1, LEU2, URA3,
HIS2, and ADE1 and a standardized selection of at least 16 unique restriction sites in their polylinkers.
Additionally, we have expanded the range of drug selection options that can be used for PCR-mediated
homologous replacement using pRS plasmid templates by replacing the G418-resistance kanMX4 cassette
of pRS400 with MX4 cassettes encoding resistance to phleomycin, hygromycin B, nourseothricin, and
bialaphos. Finally, in the process of generating the new plasmids, we have determined several errors in
existing publicly available sequences for several commonly used yeast plasmids. Using our updated
sequences, we constructed pRS plasmid backbones with a unique restriction site for inserting new markers
to facilitate future expansion of the pRS series.
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The budding yeast Saccharomyces cerevisiae is an important and
widely used model system for studying eukaryotic cell biology that
has also become important in the new ﬁelds of functional genomics
and systems biology (Botstein and Fink 2011). Among the most im-
portant tools available for the genetic manipulation of S. cerevisiae
are plasmid shuttle vectors, which can be used in both S. cerevisiae
and the bacterium Escherichia coli (Da Silva and Srikrishnan 2011;
Iserentant 1990). In addition to an antibiotic resistance marker and
a bacterial replication origin for propagation in E. coli, these shuttle
vectors contain a second yeast-selectable marker. The latter marker
is typically either a gene that confers resistance to antibiotics or
antifungal toxins (Van Den Berg and Steensma 1997) or a biosyn-
thetic gene that rescues an auxotrophic mutation (Pronk 2002).
Today, most commonly encountered S. cerevisiae shuttle vectors be-
long to one of three classes (Da Silva and Srikrishnan 2011; Iserentant
1990; Romanos et al. 1992): (1) integrating plasmids (YIp), which lack
yeast replication origins, must be inserted into the yeast genome in
order to be replicated; (2) centromere plasmids (YCp), which contain
both a yeast centromere (CEN) and an autonomously replicating se-
quence (ARS), are replicated in yeast at single or very low copy num-
ber; or (3) yeast episomal plasmids (YEp), which contain a 2m circle
replication origin and the cis-acting STB (stability) locus (Mehta et al.
2002), are replicated autonomously in yeast at high copy number.
Among the shuttle vectors most frequently used today by
researchers working with S. cerevisiae are the YXplac series (Gietz
and Sugino 1988) and the pRS series (Brachmann et al. 1998;
Christianson et al. 1992; Sikorski and Hieter 1989). The systematic
design and utility of these plasmids have inspired the construction of
similar plasmid sets for use in other fungal model organisms (Adams
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Volume 2 | May 2012 | 515et al. 2005; Chen 1996; Gould et al. 1992). The YXplac series is based
on the plasmid pUC19 (Gietz and Sugino 1988), whereas the pRS
series uses a hybrid backbone built using either the pBluescript or
pBluescriptII polylinker/multiple cloning site (MCS) ligated to the
pBluescribe replication origin (Christianson et al. 1992; Sikorski and
Hieter 1989). Compared with older and larger pBR322-based yeast
vectors (Botstein et al. 1979; Kuo and Campbell 1983; Tschumper and
Carbon 1980), both the YXplac and pRS series offer important advan-
tages of small plasmid sizes (,7 kb), high copy number in bacteria,
a good range of unique sites for cloning, the capacity for blue-white
screening, and a range of yeast-selectable markers. These markers
include the S. cerevisiae biosynthetic genes TRP1, LEU2,a n dURA3,
which can be used with almost all commonly encountered laboratory
strains that are auxotrophic for tryptophan, leucine, or uracil, respec-
tively. However, there are limitations to both series with respect to
histidine and adenine auxotrophy. First, the YXplac series does not
include prototrophic markers that can be used in strains that are
either His2 and/or Ade2 (Gietz and Sugino 1988). Second, although
the pRS series does include plasmids marked with either HIS3
(Christianson et al. 1992; Sikorski and Hieter 1989) or ADE2 (Brachmann
et al. 1998), not all common laboratory strains that are His2 and/or
Ade2 carry HIS3 and/or ADE2 mutations; the strains BF264-15D
(abbreviated as 15D) (Reed et al. 1985), J17 (Fitzgerald-Hayes et al.
1982), and B93 (Vezhinet et al. 1991) are examples of his2 ade1
mutants. Given that auxotrophic markers are important for facilitat-
ing the genetic manipulation of S. cerevisiae (Pronk 2002), the in-
ability to conveniently exploit all the available auxotrophic markers
in a given laboratory strain is an unfortunate limitation.
Our need to exploit the his2 mutation in 15D inspired the con-
struction of the integrating plasmid pRS306H2 (Chee and Haase
2010). Despite its utility, pRS306H2 suffers from an acute shortage
of unique sites in its MCS. This highlights another shortcoming of the
pRS series plasmids. The choice of restriction sites for cloning con-
structs into pRS plasmids is marker-dependent and may complicate
in vitro cloning. This is due to the presence of several restriction sites
within the S. cerevisiae HIS3, TRP1, LEU2, URA3 and other yeast-
selectable marker sequences of the pRS plasmids that are also found in
the pBluescript/pBluescript II MCS of the pRS plasmid backbone
(Brachmann et al. 1998; Eriksson et al. 2004; Sikorski and Hieter
1989). This is in contrast to the YXplac series (Gietz and Sugino
1988) in which TRP1, LEU2,a n dURA3 markers were mutagenized
to remove restriction sites in common with the pUC19 MCS. Hence,
all 10 of the 6-bp restriction sites in the pUC19 MCS are unique in
every YXplac plasmid (Gietz and Sugino 1988). If constrained by
restriction site availability, an investigator seeking to integrate a construct
of interest into the yeast genome using a particular pRS plasmid would
have to ﬁrst clone a given construct into another integrating plasmid
with a different marker or into an episomal plasmid by using recom-
bination-mediated/gap-repair methods (Ma et al. 1987; Oldenburg
et al. 1997) before moving it into the integrating plasmid with the
desired marker using PvuIo rBssHII fragment exchange (Brachmann
et al. 1998; Sikorski and Hieter 1989). However, given the additional
labor and time required, this may not be an ideal solution for
everyone.
In addition to introducing genetic constructs into yeast and in vivo
cloning by homologous recombination, the pRS series of vectors can
also be used for PCR-mediated homologous replacement of sequences
in the budding yeast genome (Baudin et al. 1993; Brachmann et al.
1998; Replogle et al. 1999). This method allows for sequences in the
S. cerevisiae genome to be replaced by a selectable marker ampliﬁed by
PCR with 59 and 39 ﬂanking sequences matching the sequences up-
stream and downstream of the sequence of interest (Baudin et al.
1993; Lorenz et al. 1995; Wach 1996). The simplicity and utility of
PCR-mediated gene replacement has led to its usage in other fungal
model organisms as well (Kaur et al. 1997; Walther and Wendland
2008; Wendland et al. 2000). Due to the standardized design of the
pRS series, a single pair of oligonucleotide primers can be used to
amplify any prototrophic marker from any pRS plasmid (Brachmann
et al. 1998) for transforming yeast.
Heterologous dominant drug resistance markers, such as the
kanMX module that confers resistance to G418 (Wach et al. 1994),
provide some advantages over prototrophic biosynthetic markers for
PCR-mediated gene disruption/deletion. Although using a prototro-
phic marker requires working with a strain that carries the corre-
sponding auxotrophic mutation, no such requirement exists for
drug resistance markers. Moreover, whereas the usage of drug resis-
tance genes is more ﬂexible as they lack homology to the S. cerevisiae
genome (Goldstein and McCusker 1999), prototrophic markers de-
rived from S. cerevisiae work best in strains with “designer deletion
alleles” (Brachmann et al. 1998; Replogle et al. 1999), in which gene
conversion or rescue of the corresponding auxotrophic mutation is
prevented. Finally, whereas prototrophic markers have the potential to
complicate phenotypic analysis and must be carefully controlled for
(Pronk 2002), drug resistance markers reportedly have neutral effects
on growth under non-selective conditions (Goldstein and McCusker
1999; Hadﬁeld et al. 1990).
Although plasmids that carry other MX markers, such as hphMX,
natMX, and patMX (Goldstein and McCusker 1999; Hentges et al.
2005; Wach et al. 1994), have been developed using the pFA back-
bone, pRS400 (Brachmann et al. 1998) is the only pRS plasmid in the
literature that carries an MX drug resistance cassette, namely,
kanMX4 (Wach et al. 1994). On the other hand, the pRS series offers
an unmatched selection of prototrophic markers for PCR-mediated
replacement. Hence, researchers may ﬁnd themselves employing two
or more pairs of oligonucleotides to replace a particular gene sequence
with markers from different plasmid series.
In this report, we describe our attempts to overcome the limitations
described above. First, we have constructed new HIS2-a n dADE1-
marked shuttle vectors by replacing the yeast-selectable marker of
existing pRS plasmids. In each of these new plasmid vectors, we have
preserved the uniqueness of all 18 common restriction sites found in
their polylinker regions, providing valuable new tools for genetic anal-
ysis in his2 and ade1 laboratory yeast strains.
Second, to expand the availability of unique sites in the MCS of
existing pRS plasmids, we have mutagenized the S. cerevisiae genes
ADE2, HIS3, TRP1, LEU2,a n dURA3 using a strategy similar to that
used during the construction of theY X p l a cs e r i e s( G i e t za n dS u g i n o
1988). We also swapped the 2m origin of the pRS episomal vectors with
that from the YEplac series so as to remove the XbaI site within.
A l t o g e t h e r ,w eh a v eg e n e r a t e d4 2p R SII plasmid shuttle vectors with
16 restriction sites in their polylinkers that are unique throughout the
entire series: pRSII30x/31x/32x with the pBluescript KS+ MCS (Sikorski
and Hieter 1989) and pRS40x/41x/42x with the pBluescript II SK+
MCS (Brachmann et al. 1998; Christianson et al. 1992). The pRSII
plasmids are easier to manipulate in vitro than their pRS predecessors
and will facilitate molecular cloning and yeast plasmid construction.
Third, we have expanded the repertoire of drug resistance cassettes
available in pRS plasmids and, hence, the number of markers that can
be ampliﬁed using a single pair of oligonucleotides for PCR-mediated
gene replacement. We replaced the kanMX4 cassette in pRS400 with
four drug resistance genes, derived from other commonly used plas-
mids (Goldstein and McCusker 1999; Gueldener et al. 2002), that
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ycin B, nourseothricin, and bialaphos.
Finally, in the course of constructing our new plasmids, we have
uncovered several errors in publicly accessible nucleotide sequences
for existing yeast plasmids. These errors probably went unnoticed
because the restriction maps for these plasmids were based on the
published sequences of the different parts used to build them. Some of
these errors caused restriction sites to be missed while suggesting the
presence of non-existent sites. One error in the sequence for pRS402,
pRS412, and pRS422 (Brachmann et al. 1998) is particularly serious as
it fails to document the presence of a 163-bp insertion in these plas-
mids that causes a drastic reduction in yield when one attempts to
amplify the ADE2 marker with standard pRS primers. Another error
that required rectiﬁcation was the opposite orientation of the CEN6/
ARSH4 cassette in pRS313 and pRS413 compared to all other pRS
CEN plasmids. We have documented the sequence discrepancies we
observed to improve the accuracy of molecular cloning. Importantly,
the true sequence of the ADE2 and LEU2 pRS vectors facilitated the
construction of pRS backbone plasmids with a unique restriction site
(BglII and AgeI, respectively) located between the two pRS primer
binding sites. Novel yeast-selectable markers of the user’sc h o i c e
may therefore be easily introduced to construct additional pRS vectors
in the future.
MATERIALS AND METHODS
Plasmid construction
Standard techniques were used for DNA manipulation. Restriction
enzymes were purchased from New England Biolabs, except for PfoI,
which was purchased from Fermentas. Ligations were performed us-
ing T4 DNA ligase purchased from Invitrogen. Both PCR-mediated
site-directed mutagenesis and gene ampliﬁcation for cloning purposes
were performed using either cloned Pfu Turbo DNA polymerase
(Stratagene) or KOD HotStart DNA polymerase (Toyobo, Novagen/
EMD Chemicals). Antarctic phosphatase (New England Biolabs) was
used to treat symmetrical ends of plasmids cut with a single restriction
enzyme to prevent recircularization. Plasmid propagation was carried
out in Invitrogen MAX Efﬁciency DH5a bacteria grown in lysogeny
broth (LB) (Bertani 2004) supplemented with either 50–100 mg/ml
ampicillin sodium salt or 10 mg/ml kanamycin sulfate purchased from
Sigma-Aldrich. Bacterial transformants were selected for on LB 2%
agar plates supplemented with either 100 mg/ml ampicillin sodium
salt or 60 mg/ml kanamycin sulfate.
Plasmid construction details are provided in supporting informa-
tion, File S1. In general, we followed the strategy employed for mu-
tagenesis of TRP1, LEU2,a n dURA3 during construction of the
YXplac plasmids (Gietz and Sugino 1988). We used silent mutations
that preserve the amino acid sequence to mutagenize restriction sites
found in the open reading frame of the yeast-selectable auxotrophic
marker genes ADE2, HIS3, TRP1, LEU2, URA3, ADE1,a n dHIS2
(Table S1). As for the few sites occurring in the untranslated regions
of these genes, we used neutral changes that should not affect either
transcription initiation or termination. Oligonucleotides used for site-
directed mutagenesis are listed in Table S2.
In silico cloning
The software ApE (M. Wayne Davis, University of Utah, http://biologylabs.
utah.edu/jorgensen/wayned/ape/) and pDRAW32 (Acaclone Software,
http://www.acaclone.com/) were used to analyze sequence data, design pri-
mers, and design cloning strategies. Additionally, PlasMapper 2.0 (Dong
et al. 2004) and BVTech Plasmid 5.1 (Bio Visual Tech Inc.) were used to
generate the plasmid maps shown in the ﬁgures.
Yeast strains and media
Two auxotrophic wild-type strains of budding yeast were used to
verify the ability of the pRSII plasmids described in this report to
rescue auxotrophic mutations. The ﬁrst is 15Daub (Kaiser et al. 1999),
a bar1D ura3Dns derivative of BF264-15D (MATa ade1 his2
leu2-3,112 trp1-1a) (Reed et al. 1985), abbreviated as 15D in our lab.
The second is a bar1D derivative of W303a (MATa ade2-1 his3-11,15
leu2-3,112 trp1-1 ura3-1 can1-100) (Elion et al. 1993), also known as
SBY688 in our lab. The prototrophic yeast strain S288C (MATa SUC2
gal2 mal mel ﬂo1 ﬂo8-1 hap1 ho bio1 bio6) (Mortimer and Johnston
1986), also known as SBY1806 in our lab, was used to verify the utility
of our new pRS plasmids carrying MX4 drug resistance cassettes in
PCR-mediated gene replacement (File S1). Yeast cultures were grown
in standard YEPD medium (1% yeast extract, 2% peptone, 0.012%
adenine, 0.006% uracil, and 2% dextrose), except during selection;
plate media were prepared by adding 2% agar. Growth temperatures
were kept between 25 and 26. Prototrophic transformants were
selected for by plating on synthetic complete dropout plates (0.67%
yeast nitrogen base, 2% dextrose, 2% agar) lacking the appropriate
amino acid or nucleobase. To select for drug-resistant transformants,
we suggest referring to previously published protocols for guidelines
(Baudin et al. 1993; Gatignol et al. 1987; Goldstein and McCusker
1999; Wenzel et al. 1992). Selection conditions that we have tested
ourselves and suggestions for users who experience difﬁculty with
drug selection are described in File S1.
PCR protocol for amplifying pRS/pRSII plasmid
yeast-selectable markers
Similarly to what has previously been described (Brachmann et al.
1998), we used primers starting with 40–50 nucleotides of gene-
speciﬁcs e q u e n c ea tt h e5 9 end and followed by either 59-CAGATTG
TACTGAGAGTGC-39 (pRS forward primer binding site) or 59-
CCTTACGCATCTGTGCGG-39 (pRS reverse primer binding site)
to amplify the yeast-selectable marker sequences in any of the pRS
or pRSII plasmids; examples of primer pairs used to target the genes
KIP1, CIN8,a n dADE2 are provided in Table S3.A sn o t e db e f o r e
(Goldstein and McCusker 1999), PCR ampliﬁcation of the natMX4
and patMX4 drug resistance cassettes requires the addition of 5%
DMSO. The reaction parameters we employed were: 94 for 1 min
followed by 34 ampliﬁcation cycles (94 for 45 sec, 55 for 45 sec, 72
for 1 min/kb of expected PCR product size), 72 for 10 min. Anneal-
ing and denaturation times can be shortened to 30 sec, and the
extension temperature can be reduced to 70 or 68. Taq DNA
polymerase (Denville) was used for marker ampliﬁcation at 0.05ml.
Yeast transformation
Yeast were transformed using high-efﬁciency methods involving
lithium acetate, polyethylene glycol, and denatured, single-stranded
salmon sperm DNA (Gietz and Schiestl 2007; Gietz and Woods 2001).
To transform the wild-type strains 15Daub and W303a using pRS/
pRSII plasmids, we used either 200 ng of integrating plasmid linear-
ized by restriction at a unique site within the yeast-selectable
prototrophic marker sequence or 50 ng of CEN/2m plasmid. Proto-
trophic transformants were selected for by spinning down yeast cells
after heat shocking and resuspending them in sterile water before
plating on the appropriate dropout medium. For drug selection, the
yeast were resuspended in YEPD and allowed to recover before
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resistance cassettes is described in detail in File S1.
RESULTS AND DISCUSSION
New HIS2-marked yeast-bacteria shuttle vectors
Whereas S. cerevisiae HIS3 encodes imidazoleglycerol-phosphate
dehydratase, HIS2 encodes histidinolphosphatase. Both of these
enzymes function in histidine biosynthesis but catalyze different steps
(Alifano et al. 1996; Gorman and Hu 1969; Struhl and Davis 1980).
Despite the availability of plasmids that can be used with histidine
auxotrophic laboratory strains of budding yeast that are his3 mutants,
these plasmids cannot be used with His2 strains that are his2 mutants.
The latter includes include strains such as 15D (Reed et al. 1985),
which is widely used in cell-cycle research. The comparative scarcity
of HIS2-marked yeast vectors poses an unnecessary limitation when
working with his2 strains. Our ﬁrst attempt at making an integrating
vector with a HIS2 marker involved the disruption of the URA3
marker in pRS306 (Sikorski and Hieter 1989) with a wild-type HIS2
allele, resulting in pRS306H2 (Chee and Haase 2010). Although this
plasmid has been successfully used to both integrate genetic constructs
into the S. cerevisiae genome (Chee and Haase 2010) and to delete
genes of interest by PCR (unpublished data), it suffers from a shortage
of unique sites in its MCS, contains extraneous sequences, and could
be streamlined (Figure 1A). Moreover, HIS2-marked centromere and
2m episomal versions of pRS306H2 have yet to be constructed.
To improve upon pRS306H2, we have completely rebuilt it using
a different strategy (File S1). Using a site-directed mutagenesis strategy
similar to that of Gietz and Sugino (1988), we removed the BamHI
and XhoI sites present in the wild-type HIS2 gene (Table S1 and File
S1). We subsequently used the mutagenized HIS2, PCR-ampliﬁed
with NdeIa n dNsiI ends, to replace almost the entire URA3 gene in
pRS306. The resulting plasmid, which we have dubbed pRSII309, is
the updated successor to pRS306H2. pRSII309 is 0.4 kb smaller than
its predecessor due mostly to the near-complete excision of the URA3
marker from pRS306 (Figure 1); in pRS306H2, the URA3 marker was
disrupted between the NcoIa n dNsiI sites. Moreover, all of the 18
common restriction sites in the pRSII309 polylinker region (the
pBluescript KS+ MCS) are unique. This replacement method is sim-
ilar to the one we used to generate pRS306H2 in that it can be used to
convert other URA3-marked yeast plasmids to the HIS2 marker (Chee
and Haase 2010). We subsequently constructed CEN and 2m episomal
derivatives of pRSII309, pRSII319 and pRSII329, respectively, as well
as pRSII409/419/429, which carry the pBluescript II SK+ MCS (Table
1a n dFile S1). The signiﬁcance of the pRSII designation is explained
below.
New ADE1-marked shuttle vectors
Adenine auxotrophy presents an analogous problem to that we have
described for histidine auxotrophy in S. cerevisiae. S. cerevisiae ADE1
encodes N-succinyl-5-aminoimidazole-4-carboxamide ribotide syn-
thetase, whereas ADE2 encodes phosphoribosylaminoimidazole car-
boxylase, enzymes required for distinct steps in de novo purine
biosynthesis (Jones and Fink 1982; Myasnikov et al. 1991; Stotz and
Linder 1990). Ade2 strains that carry ade1 and/or ade2 mutations
accumulate a red pigment that distinguishes them from Ade+ yeast,
which are white (Fisher 1969; Silver and Eaton 1969). Hence, ade1,
ade2 as well as ade1 ade2 mutants are valuable for visual red-white
screening of transformants and other color-based assays (Ugolini and
Bruschi 1996; Weng and Nickoloff 1997). However, as ADE2-marked
plasmids are not useful when working with ade1 mutant strains,
investigators would beneﬁtf r o mh a v i n gas e to fADE1-marked pRS
plasmids available to complement existing ADE2 pRS plasmids
(Brachmann et al. 1998).
Without pre-existing ADE1 shuttle vectors in hand, we chose the
ADE2-marked pRS402 (Brachmann et al. 1998) to build an ADE1-
marked integrating plasmid. Based on its GenBank sequence (acces-
sion no. U93717.1), the ADE2 marker in pRS402 is ﬂanked by BglII
sites and is thus easily replaced (Figure 2A); however, we discovered
disagreements between the actual and the GenBank sequences of
pRS402 when performing restriction analysis and Sanger sequencing.
First, restricting pRS402 (Brachmann et al. 1998) with NdeI yields two
fragments (1.9 and 3.8 kb) instead of the single 5.5 kb molecule
predicted by its GenBank sequence. Moreover, we could not sequence
pRS402 using a standard pRS reverse primer (59-CCTTACGCAT
CTGTGCGG-39) as Sanger capillary sequencing reactions consistently
returned overlapping electropherograms, strongly suggesting that the
primer was annealing to two different sites on the plasmid.
By sequencing with other primers (Table S4), we determined the
presence of an undocumented insertion in pRS402 (Figure 2A) that
contains an unwanted second pRS reverse primer binding site, which
we ﬁrst had to remove along with the ADE2 marker, and then gen-
erate a pRS backbone plasmid with a unique BglII site (Figure 2A). We
also mutagenized the ADE1 gene to remove ﬁve restriction sites that
are found in the pBluescript/pBluescript II MCS similarly to what we
did to HIS2 (Table S1 and File S1). Next, we subcloned the mutagen-
ized ADE1 marker into the BglII site to generate pRSII408 (Figure 2B).
As the same unwanted insertion was found in both pRS412 and
pRS422 (Brachmann et al. 1998), we used a similar strategy to con-
struct pRSII418 (CEN) and pRSII428 (2m) and subsequently generated
pRSII308/318/328. As with their HIS2-marked counterparts, all 18
common restriction sites in the polylinker region of the new ADE1
pRSII plasmids are unique (Table 1).
A second generation of pRS plasmids (pRSII)
with expanded unique restriction site selection
within the polylinker region
Due to the existence of restriction sites common to both their yeast-
selectable marker sequences as well as their polylinker regions, unique
site selection within the MCS of current pRS plasmids is marker-
dependent (Christianson et al. 1992; Sikorski and Hieter 1989). As
shown in Table S1, only 9 of the 18 common restriction sites in the
MCS of existing pRS vectors marked with either ADE2, HIS3, TRP1,
LEU2,o rURA3 are unique across the board; this number drops to 7 if
the MET15, LYS2,a n dADE8 markers found in other pRS series
plasmids (Brachmann et al. 1998; Eriksson et al. 2004; Tomlin et al.
2001) are also considered (data not shown). Additionally, the 2m pRS
plasmids (Christianson et al. 1992) carry an XbaI site within the
2m replication origin originally derived from YEp24 (Hartley and
Donelson 1980). As a consequence, the XbaI site in the pRS42x
MCS is not unique.
In contrast to the pRS series, the S. cerevisiae TRP1, LEU2,a n d
URA3 alleles used to construct the YXplac series of shuttle vectors
were mutagenized to remove all 6-bp restriction sites that are also
found in the pUC19 MCS (Gietz and Sugino 1988) of that series.
Additionally, the XbaI site within the 2m origin from YEp24 (Hartley
and Donelson 1980) was removed before it was incorporated into the
2m YXplac (YEplac) plasmids (Gietz and Sugino 1988). Hence, all 10
of the 6-bp sites in the pUC19 MCS (59-EcoRI-SacI-KpnI-SmaI-
BamHI-XbaI-SalI-PstI-SphI-HindIII-39) are unique throughout the
YXplac series. Removal of the XbaIs i t ei nt h e2 m origin of YEplac195
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YEp351 and YEp352 (Hill et al. 1986) does not appear to signiﬁcantly
alter their copy number, estimated by Southern blotting, when com-
pared to the pRS42x plasmids (Christianson et al. 1992; Li and Johnston
2001; Vashee and Kodadek 1995; Velmurugan et al. 2000).
Removing common restriction sites outside the MCS: When building
our new HIS2 and ADE1 shuttle vectors, we emulated the efforts of
Gietz and Sugino (1988) and kept all the common restriction sites in
the polylinker region unique by mutagenizing the two marker genes.
We subsequently explored the feasibility of altering the prototrophic
marker sequences (Figure 3) of other commonly used pRS plasmids
to both increase the availability of unique sites in their polylinkers as
well as to standardize unique site selection across the series. To do so
in an efﬁcient manner, we wanted to subclone the TRP1, LEU2, and
URA3 alleles developed for the YXplac series into the pRS series
Figure 1 Features of new S. cerevisiae HIS2-marked plasmid shuttle vectors. (A) Restriction maps of the integrating plasmids pRS306H2 (Chee
and Haase 2010) and pRSII309. (B) Episomal plasmids pRSII319 (CEN) and pRSII329 (2m). Although the features of each plasmid are drawn to
scale, the size of the maps are not scaled according to plasmid size. Aside from the two NdeI sites highlighted in red for pRS306H2, only unique
restriction sites are shown and isoschizomers are indicated.
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ADE2. Additionally, to make the XbaI site within the MCS of the
pRS 2m plasmids unique, we wanted to replace their 2m origin with
that from YEplac195 (Gietz and Sugino 1988).
After the reconstruction detailed in File S1, we have reduced re-
striction site overlap between the ﬁve markers and the pBluescript/
pBluescript II MCS to the point where 16 of the 18 common restric-
tion sites in the polylinker region of our pRSII plasmid series are
universal; EcoRV and BstXI, one or both of which occur in all ﬁve
mutagenized markers (Figure 3), were the only sites we left intact
(Table 1). We did not initially plan to mutagenize the ApaI site in
the URA3 marker because it overlaps with a dcm methylation site
(Larimer 1987) and most laboratory bacterial strains are dcm+;h o w -
ever, we found that ApaI is able to cleave pRS306 isolated from dcm+
DH5a E. coli at this site (data not shown), underscoring the difﬁculty
of predicting inhibitory effects by site-speciﬁc DNA methylation
(McClelland et al. 1994). As a result, we removed the site altogether.
The ability of the modiﬁed prototrophic markers to rescue their
corresponding auxotrophic mutations in yeast was veriﬁed by trans-
forming the auxotrophic wild-type strains 15Daub (Kaiser et al. 1999)
and W303a (Elion et al. 1993) with the new pRSII plasmids. Side-by-
side transformations were done with existing pRS plasmids for com-
parison, except for the modiﬁed HIS2 and ADE1 alleles described
above. For HIS2 and ADE1, comparisons were made by transforming
15Daub with TA cloning plasmids containing either the unmodiﬁed
or the mutagenized alleles (pGEM-T-HIS2 and pDrive-ADE1, File S1),
which act as yeast integrating plasmids when linearized (see Materials
and Methods). We observed no signiﬁcant differences in transforma-
tion efﬁciency (data not shown).
Correcting aberrant features in existing pRS plasmids: In the course
of building our pRSII plasmids, we discovered aberrant features in ﬁve
pRS plasmids that contradict the intended uniform design of that
plasmid series. We have either removed or corrected these in our
n Table 1 pRSII series plasmids
Plasmid Names Yeast-selectable Marker Yeast Replication Origin MCS
Non-unique Restriction Sites
Remaining in MCS Addgene ID
pRSII302 ADE2 None pBluescript KS+ EcoRV, BstXI 35433
pRSII402 ADE2 None pBluescript II SK+ EcoRV, BstXI 35434
pRSII303 HIS3 None pBluescript KS+ BstXI 35435
pRSII403 HIS3 None pBluescript II SK+ BstXI 35436
pRSII304 TRP1 None pBluescript KS+ EcoRV, BstXI 35437
pRSII404 TRP1 None pBluescript II SK+ EcoRV, BstXI 35438
pRSII305 LEU2 None pBluescript KS+ EcoRV, BstXI 35439
pRSII405 LEU2 None pBluescript II SK+ EcoRV, BstXI 35440
pRSII306 URA3 None pBluescript KS+ EcoRV 35441
pRSII406 URA3 None pBluescript II SK+ EcoRV 35442
pRSII308 ADE1 None pBluescript KS+ None 35443
pRSII408 ADE1 None pBluescript II SK+ None 35444
pRSII309 HIS2 None pBluescript KS+ None 35445
pRSII409 HIS2 None pBluescript II SK+ None 35446
pRSII312 ADE2 CEN6/ARSH4 pBluescript KS+ EcoRV, BstXI 35447
pRSII412 ADE2 CEN6/ARSH4 pBluescript II SK+ EcoRV, BstXI 35448
pRSII313 HIS3 CEN6/ARSH4 pBluescript KS+ BstXI 35449
pRSII413 HIS3 CEN6/ARSH4 pBluescript II SK+ BstXI 35450
pRSII314 TRP1 CEN6/ARSH4 pBluescript KS+ EcoRV, BstXI 35451
pRSII414 TRP1 CEN6/ARSH4 pBluescript II SK+ EcoRV, BstXI 35452
pRSII315 LEU2 CEN6/ARSH4 pBluescript KS+ EcoRV, BstXI 35453
pRSII415 LEU2 CEN6/ARSH4 pBluescript II SK+ EcoRV, BstXI 35454
pRSII316 URA3 CEN6/ARSH4 pBluescript KS+ EcoRV 35455
pRSII416 URA3 CEN6/ARSH4 pBluescript II SK+ EcoRV 35456
pRSII318 ADE1 CEN6/ARSH4 pBluescript KS+ None 35457
pRSII418 ADE1 CEN6/ARSH4 pBluescript II SK+ None 35458
pRSII319 HIS2 CEN6/ARSH4 pBluescript KS+ None 35459
pRSII419 HIS2 CEN6/ARSH4 pBluescript II SK+ None 35460
pRSII322 ADE2 2m ORI-STB pBluescript KS+ EcoRV, BstXI 35461
pRSII422 ADE2 2m ORI-STB pBluescript II SK+ EcoRV, BstXI 35462
pRSII323 HIS3 2m ORI-STB pBluescript KS+ BstXI 35463
pRSII423 HIS3 2m ORI-STB pBluescript II SK+ BstXI 35464
pRSII324 TRP1 2m ORI-STB pBluescript KS+ EcoRV, BstXI 35465
pRSII424 TRP1 2m ORI-STB pBluescript II SK+ EcoRV, BstXI 35466
pRSII325 LEU2 2m ORI-STB pBluescript KS+ EcoRV, BstXI 35467
pRSII425 LEU2 2m ORI-STB pBluescript II SK+ EcoRV, BstXI 35468
pRSII326 URA3 2m ORI-STB pBluescript KS+ EcoRV 35469
pRSII426 URA3 2m ORI-STB pBluescript II SK+ EcoRV 35470
pRSII328 ADE1 2m ORI-STB pBluescript KS+ None 35471
pRSII428 ADE1 2m ORI-STB pBluescript II SK+ None 35472
pRSII329 HIS2 2m ORI-STB pBluescript KS+ None 35473
pRSII429 HIS2 2m ORI-STB pBluescript II SK+ None 35474
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design. Signiﬁcantly, we rebuilt the three ADE2 pRS plasmids to
remove the undocumented insertion mentioned earlier that is found
in pRS402/412/422 (Figure 2A). This 163-bp insertion is a near-iden-
tical repeat of the sequence immediately ﬂanking the 39 end of the
ADE2 marker (162 out of the 163 nucleotides are identical) and thus
contains a binding site for standard pRS reverse primers that lies
between the pRS forward primer binding site and the ADE2 marker.
This extra reverse primer binding site greatly reduces the yield of any
attempt to amplify the ADE2 marker by PCR for homologous gene
replacement in yeast (Figure S1).
We also determined that the CEN6/ARSH4 cassette in pRS313 and
pRS413 was inserted in the opposite orientation to those in other pRS
CEN plasmids. During construction of the pRS31x plasmids (Sikorski
and Hieter 1989), the authors had intended for the CEN6/ARSH4
cassette to be inserted such that CEN6 would be closest to the bla
gene, but CEN6 i si n s t e a dc l o s e rt ot h eHIS3 marker in both pRS313
and pRS413. We have corrected this inconsistency during the con-
struction of pRSII313 and pRSII413 (File S1).
pRSII plasmid features: Our initial set of 42 pRSII integrating,
centromere and 2m episomal plasmids are listed in Table 1; as these
plasmids will be made available through Addgene, the corresponding
Addgene plasmid IDs are indicated. The naming conventions estab-
lished for the pRS plasmid series (Brachmann et al. 1998; Christianson
et al. 1992; Sikorski and Hieter 1989) also apply to the pRSII plasmids
(Table 1 and Table S1). The elimination of common 6-bp restriction
sites like KpnI, HindIII, EcoRI, and XbaI from the seven prototrophic
marker gene sequences (Figure 3) makes it more convenient to clone
inserts into the pRSII polylinker and also simpliﬁes the movement
of inserts between pRSII plasmids. As has been described, a PvuI
digest can be used to exchange inserts between pRS300-series and
between pRS400-series plasmids (Sikorski and Hieter 1989), and
BssHII can be used to exchange inserts only between pRS400-
series plasmids (Brachmann et al. 1998), features that are inherent
to the backbone and remain unchanged in their pRSII counter-
parts. As we have also maintained the characteristic uniform
structure of the pRS series in our pRSII plasmids, they are com-
patible with the many sets of pRS-based plasmids that have been
Figure 2 Features of existing S. cerevisiae ADE2 and new ADE1-marked plasmid shuttle vectors. (A) Restriction maps of pRS402 built using
existing GenBank (left) and experimentally determined (right) sequence data. A previously undocumented 163-base pair insertion indicated in
dark purple; this insertion is a nearly identical repeat of 163 nucleotides 39 of the ADE2 marker and hence carries an extra pRS reverse primer
binding site (highlighted). This repeat was removed to generate the pRS backbone plasmid pRS40BglII (B) that was subsequently used to
construct pRSII402 and pRSII408. (C) Restriction maps of pRSII408, pRSII418, and pRSII428. Unique restriction sites are shown in black, and
non-unique BglII and NdeI sites are shown in red; isoschizomers are also indicated.
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expression in yeast, and recombination cloning. By adapting the
added features of such existing plasmids to the pRSII backbone,
derivatives with a standardized M C S ,d i f f e r i n go n l yi nt h ey e a s t -
selectable marker that they carry, can easily be generated.
Users should be take note of the addendum in the original paper
that described the initial set of pRS plasmids (Sikorski and Hieter
1989). The MCS of the pRS300 (and hence the pRSII300) series
plasmids contains a single base pair deletion found in all of Strate-
gene’s pBluescript KS plasmids. This deletion removed a G immedi-
ately upstream of the KpnI site and downstream of the lacZ reporter’s
ATG start codon. Blue-white screens still work (by an unknown
mechanism) with the pRS300 (and pRSII300) series plasmids, but
users who plan to generate LacZ fusion proteins should be aware of
this frameshift. The pRS400 (and pRSII400) plasmids are not affected
by this deletion as their MCS is derived from pBluescript II KS+
(Sikorski and Hieter 1989).
New pRS plasmids with drug resistance markers
for PCR-mediated gene disruption/deletion
The introduction of the plasmid pRS400 made drug selection possible
for users of the pRS series seeking to either disrupt or delete sequences
of interest in the budding yeast genome by PCR-mediated homolo-
gous replacement (Brachmann et al. 1998). pRS400 (Figure 4A) con-
tains a heterologous kanMX4 module (Wach et al. 1994), in which the
E. coli transposon Tn903 kan gene (Grindley and Joyces 1980) is
under the control of the constitutive Ashbya gossypii TEF1 promoter.
Tn903 kan encodes aminoglycoside phosphotransferase, which con-
fers resistance to kanamycin/G418 by phosphorylating the antibiotic
(Oka et al. 1981). It should be noted, however, that the kanMX4
cassette in pRS400 is oriented in the opposite direction to what its
GenBank sequence (accession no. U93713.1) indicates (Figure 4A).
To expand the repertoire of drug resistance markers in the pRS
plasmid series, we replaced the kanMX4 cassette of pRS400 with MX4
cassettes containing drug resistance genes from other commonly used
plasmids (Goldstein and McCusker 1999; Gueldener et al. 2002) and
generated four new pRS plasmids that will also be made available
through Addgene (Table 2 and Figure 4B): (1) pRS40B contains the
gene ble, originally cloned from transposon Tn5 isolated from Kleb-
siella pneumoniae, which encodes a protein that binds with high
afﬁnity to phleomycin/bleomycin family antibiotics (Gatignol et al.
1987; Genilloud et al. 1984), such as Zeocin (Invitrogen); (2) pRS40H
contains hph from K. pneumoniae, which encodes hygromycin B
phosphotransferase for hygromycin B resistance (Gritz and Davies
1983); (3) pRS40N contains nat1,f r o mStreptomyces noursei,w h i c h
encodes nourseothricin N-acetyltransferase for resistance toward
Figure 3 Schematic diagrams of the prototrophic biosynthetic marker genes found in pRSII series plasmids. Restriction sites in each marker that
were targeted for removal before incorporation into pRSII series plasmids are indicated, as are the restriction sites that immediately ﬂank the
ADE2, LEU2, ADE1, and HIS2 markers within the pRS or pRSII plasmids. The ORF in each marker is indicated by a block arrow. A complete list of
pRSII plasmids is found in Table 1, and the oligonucleotides used for site-directed mutagenesis of restriction sites are found in Table S2. The
BamHI site found in the ADE1 genomic sequence was previously removed from the ADE1 allele (Nagley et al. 1988) used to generate pRSII408.
The BglII site found in the ADE2 genomic sequence was also previously removed (Stotz and Linder 1990) from the ADE2 allele used to generate
pRSII402. Although the ApaI site in URA3 overlaps with a dcm methylation site, plasmid DNA isolated from DH5a dcm+ bacteria is still cleaved at
this site by ApaI. The gene diagrams shown are drawn to scale.
522 | Chee and Haasenourseothricin, a mixture of streptothricins (Krügel et al. 1993); and
(4) pRS40P contains pat, from Streptomyces viridochromogenes,w h i c h
encodes phosphinothricin N-acetyltransferase for resistance to biala-
phos (Strauch et al. 1988; Wohlleben et al. 1988), to make pRS40P.
When using the above drugs to select for yeast transformants, we
recommend referring to previously suggested drug concentrations
and media recipes for guidelines (Gatignol et al. 1987; Goldstein
and McCusker 1999; Wenzel et al. 1992). We successfully tested our
Figure 4 Features of pRS400 and plas-
mids derived from it carrying new domi-
nant drug resistance MX4 cassettes that
can be ampliﬁed by PCR for gene disrup-
tion/deletion in yeast. (A) Restriction maps
of pRS400 with kanMX4 cassette for G418
resistance, based on existing GenBank
(left) and experimentally derived (right)
nucleotide sequences. The orientation of
the kanMX4 cassette is inverted in the
Genbank sequence. (B) New MX4 plas-
mids derived from pRS400. Top, pRS40B
with bleMX4 cassette for phleomycin re-
sistance (left) and pRS40H with hphMX4
cassette for hygromycin B resistance
(right). Bottom, pRS40N with natMX4 cas-
sette for nourseothricin resistance (left)
and pRS40P with patMX4 cassette for bia-
laphos resistance (right). Unique restric-
tion sites are shown in black, whereas
the NcoI sites we found to be non-unique
in the patMX4 cassette (File S1) are shown
in red; isoschizomers are also indicated.
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gene (Figure S2 and Table S5) in the wild-type yeast strain S288C
(Mortimer and Johnston 1986) and have included selection conditions
that we used (File S1).
There are now a total of 5 drug resistance MX4 markers and 10
prototrophic markers (MET15, ADE2, HIS3, TRP1, LEU2, URA3,
LYS2, ADE1, HIS2,a n dADE8) that can be ampliﬁed using a single
pair of oligonucleotides (examples given in Table S3) from known
pRS/pRSII plasmids (Brachmann et al. 1998; Sikorski and Hieter
1989; Tomlin et al. 2001) for targeted homologous replacement in
budding yeast. A suggested PCR protocol compatible with all pRS/
p R S I Ip l a s m i d si sp r o v i d e di nMaterials and Methods.A sm a n yo f
the drugs used for selection are compatible with minimal media
(File S1), it is possible to design double selection schemes involv-
ing both nutritional and drug selection. Marker exchange within
a deletion/disruption strain is also possible using the same pair of
oligonucleotides; given the identical TEF1 promoter and termina-
tor regulatory sequences found in all MX cassettes (Wach 1996;
Wach et al. 1994), exchanging one cassette for another is partic-
ularly efﬁcient (Goldstein and McCusker 1999). Additionally, the
absence of cross-resistance between the antibiotic resistance
markers allows for strains carrying more than one marker to be
selected for on media containing two or more drugs (Goldstein
and McCusker 1999).
Errors in publicly available sequences for existing
yeast plasmids
In addition to the errors in existing sequences for plasmids that we
described earlier in this report, we observed inconsistencies in existing
sequence data available for several other yeast plasmids we worked
with in the course of this study. Errors were sometimes ﬁrst detected
by unexpected differences observed in the number and sizes of
restriction fragments; however, a large number were ﬁrst determined
by Sanger sequencing, such as during the construction of pRSII304
(File S1). Sequencing the pRS plasmids was necessary to verify sus-
pected errors, as the restriction maps and sequences for the ﬁrst pRS
plasmids were generated based on published sequences of their com-
ponents available at the time (Sikorski and Hieter 1989). Plasmids
were sequenced using the oligonucleotide primers listed in Table S4,
and errors were veriﬁed by sequencing related plasmids for compar-
ison. For example, errors identiﬁed in the pRS402 GenBank sequence
were veriﬁed by sequencing pRS412 and pRS422. Errors in the back-
bone sequence common across the pRS series were also identiﬁed in
this way. Our ﬁndings reinforce sequence errors that have been
reported elsewhere for pRS416 and pRS426 (Tomlin et al. 2001) as
well as the HIS3-marked pRS vectors (http://genome-www.stanford.
edu/vectordb/vector.html). We have included details of the most sig-
niﬁcant errors we determined in sequences deposited in public data-
bases such as GenBank in File S1 and have listed sequences in need of
updating in Table S6. Accurate sequence data will greatly beneﬁt
cloning using the affected plasmids.
pRS backbone plasmids for generating future pRS
plasmids with new yeast-selectable markers
As mentioned above, using the updated sequences for the ADE2-
marked pRS plasmids, we were able to excise the additional undesired
pRS reverse primer binding site and generate pRS backbone vectors
with a unique BglII site for the insertion of new marker sequences
(File S1). Similarly, the updated sequence data that we have collected
has allowed us to generate a second set of pRS backbone vectors with
a unique AgeIs i t eb ye x c i s i n gt h eLEU2 marker from LEU2-marked
pRS plasmids using Tth111I and AgeI and subsequently recirculariz-
ing the backbone (File S1); the presence of an AgeIs i t eﬂanking the
LEU2 marker in pRS305/315/405/415/425 was previously undocu-
mented. Previous efforts to build new pRS plasmids with novel
yeast-selectable markers involved lengthy cloning processes with mul-
tiple steps (Eriksson et al. 2004; Tomlin et al. 2001). With two non-
overlapping sets of restriction enzymes that generate cohesive ends
compatible with either BglII or AgeI, our new backbone vectors pro-
vide greater ﬂexibility and should simplify the future construction of
pRS/pRSII plasmids with additional yeast-selectable markers. Our new
backbone vectors are also intended to complement the existing mar-
kerless pRS plasmids pJK142 (integrating), pGC25 (CEN), and pGC26
(2m) (Brachmann et al. 1998), which have a unique NdeIs i t ef o r
inserting yeast-selectable markers.
We hope that the new yeast plasmids introduced in this report as
well as the updated sequences for existing plasmids will provide
as u f ﬁciently complete and cost-effective set of tools for starting
research projects that employ budding yeast as a model. We also hope
that they will facilitate the development of new molecular genetic tools
for yeast research.
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